JP2010077130A - 外用組成物 - Google Patents
外用組成物 Download PDFInfo
- Publication number
- JP2010077130A JP2010077130A JP2009229984A JP2009229984A JP2010077130A JP 2010077130 A JP2010077130 A JP 2010077130A JP 2009229984 A JP2009229984 A JP 2009229984A JP 2009229984 A JP2009229984 A JP 2009229984A JP 2010077130 A JP2010077130 A JP 2010077130A
- Authority
- JP
- Japan
- Prior art keywords
- oil
- skin
- composition
- igf
- stratum corneum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 121
- 239000000341 volatile oil Substances 0.000 claims abstract description 71
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims abstract description 47
- 150000003839 salts Chemical class 0.000 claims abstract description 31
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims description 42
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 claims description 39
- 229950006790 adenosine phosphate Drugs 0.000 claims description 35
- 210000003491 skin Anatomy 0.000 abstract description 106
- 239000003921 oil Substances 0.000 abstract description 87
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 abstract description 58
- 102100037852 Insulin-like growth factor I Human genes 0.000 abstract description 58
- 210000000434 stratum corneum Anatomy 0.000 abstract description 57
- 230000036572 transepidermal water loss Effects 0.000 abstract description 51
- 230000000694 effects Effects 0.000 abstract description 41
- 230000001737 promoting effect Effects 0.000 abstract description 27
- 240000005020 Acaciella glauca Species 0.000 abstract description 10
- 235000008582 Pinus sylvestris Nutrition 0.000 abstract description 10
- 239000001293 FEMA 3089 Substances 0.000 abstract description 9
- 241000544656 Cedrus atlantica Species 0.000 abstract description 8
- 230000019612 pigmentation Effects 0.000 abstract description 8
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract description 4
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 abstract description 4
- 244000089742 Citrus aurantifolia Species 0.000 abstract description 3
- 235000008733 Citrus aurantifolia Nutrition 0.000 abstract description 3
- 230000007306 turnover Effects 0.000 abstract description 3
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract description 2
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 abstract description 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 abstract description 2
- 235000004310 Cinnamomum zeylanicum Nutrition 0.000 abstract description 2
- 239000005770 Eugenol Substances 0.000 abstract description 2
- 240000007232 Illicium verum Species 0.000 abstract description 2
- 235000008227 Illicium verum Nutrition 0.000 abstract description 2
- 241001227551 Lavandula x intermedia Species 0.000 abstract description 2
- 235000016278 Mentha canadensis Nutrition 0.000 abstract description 2
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 abstract description 2
- 240000003243 Thuja occidentalis Species 0.000 abstract description 2
- 235000008109 Thuja occidentalis Nutrition 0.000 abstract description 2
- 244000273928 Zingiber officinale Species 0.000 abstract description 2
- 235000006886 Zingiber officinale Nutrition 0.000 abstract description 2
- 229960005305 adenosine Drugs 0.000 abstract description 2
- 230000003712 anti-aging effect Effects 0.000 abstract description 2
- 229960002217 eugenol Drugs 0.000 abstract description 2
- 235000008397 ginger Nutrition 0.000 abstract description 2
- 239000001839 pinus sylvestris Substances 0.000 abstract description 2
- 239000001841 zingiber officinale Substances 0.000 abstract description 2
- 244000245214 Mentha canadensis Species 0.000 abstract 1
- 230000003190 augmentative effect Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000001385 rosmarinus officinalis l. absolute Substances 0.000 abstract 1
- 235000019198 oils Nutrition 0.000 description 78
- 238000012360 testing method Methods 0.000 description 55
- 230000028327 secretion Effects 0.000 description 35
- 239000012085 test solution Substances 0.000 description 25
- 238000005259 measurement Methods 0.000 description 24
- 238000000034 method Methods 0.000 description 22
- 235000017663 capsaicin Nutrition 0.000 description 19
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 239000010665 pine oil Substances 0.000 description 16
- 241000196324 Embryophyta Species 0.000 description 14
- 238000002156 mixing Methods 0.000 description 14
- 239000002585 base Substances 0.000 description 13
- 239000010643 fennel seed oil Substances 0.000 description 12
- 230000009471 action Effects 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 230000008859 change Effects 0.000 description 9
- 239000010668 rosemary oil Substances 0.000 description 9
- 229940058206 rosemary oil Drugs 0.000 description 9
- 239000010617 anise oil Substances 0.000 description 8
- 239000001279 citrus aurantifolia swingle expressed oil Substances 0.000 description 8
- 208000012641 Pigmentation disease Diseases 0.000 description 7
- 208000003251 Pruritus Diseases 0.000 description 7
- 230000032683 aging Effects 0.000 description 7
- 239000010627 cedar oil Substances 0.000 description 7
- 230000007803 itching Effects 0.000 description 7
- 235000011613 Pinus brutia Nutrition 0.000 description 6
- 241000018646 Pinus brutia Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 6
- 229960002504 capsaicin Drugs 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 235000006679 Mentha X verticillata Nutrition 0.000 description 5
- 235000002899 Mentha suaveolens Nutrition 0.000 description 5
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 5
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 238000007405 data analysis Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000009759 skin aging Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- RBCYRZPENADQGZ-UHFFFAOYSA-N Dihydrocapsiate Chemical compound COC1=CC(COC(=O)CCCCCCC(C)C)=CC=C1O RBCYRZPENADQGZ-UHFFFAOYSA-N 0.000 description 4
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 4
- 206010048218 Xeroderma Diseases 0.000 description 4
- 206010000496 acne Diseases 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 230000036074 healthy skin Effects 0.000 description 4
- 206010021198 ichthyosis Diseases 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- RGOVYLWUIBMPGK-UHFFFAOYSA-N nonivamide Chemical compound CCCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 RGOVYLWUIBMPGK-UHFFFAOYSA-N 0.000 description 4
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- -1 phosphate ester Chemical class 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 4
- 230000037303 wrinkles Effects 0.000 description 4
- TZZAKSLHHIJRLL-UHFFFAOYSA-N 4-hydroxy-3-methoxybenzamide Chemical compound COC1=CC(C(N)=O)=CC=C1O TZZAKSLHHIJRLL-UHFFFAOYSA-N 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 206010064127 Solar lentigo Diseases 0.000 description 3
- 229960001456 adenosine triphosphate Drugs 0.000 description 3
- 238000003287 bathing Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 108010088102 mouse insulin-like growth factor-1 Proteins 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000036548 skin texture Effects 0.000 description 3
- UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 description 2
- LNQVTSROQXJCDD-KQYNXXCUSA-N 3'-AMP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@H]1O LNQVTSROQXJCDD-KQYNXXCUSA-N 0.000 description 2
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000002566 Capsicum Nutrition 0.000 description 2
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 2
- 235000002568 Capsicum frutescens Nutrition 0.000 description 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 239000006002 Pepper Substances 0.000 description 2
- 235000016761 Piper aduncum Nutrition 0.000 description 2
- 240000003889 Piper guineense Species 0.000 description 2
- 235000017804 Piper guineense Nutrition 0.000 description 2
- 235000008184 Piper nigrum Nutrition 0.000 description 2
- 241001247145 Sebastes goodei Species 0.000 description 2
- QDFHPFSBQFLLSW-UHFFFAOYSA-N UNPD78433 Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1OP(O)(O)=O QDFHPFSBQFLLSW-UHFFFAOYSA-N 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- QDFHPFSBQFLLSW-KQYNXXCUSA-N adenosine 2'-phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1OP(O)(O)=O QDFHPFSBQFLLSW-KQYNXXCUSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 229940011037 anethole Drugs 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000012459 cleaning agent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 2
- 229940043276 diisopropanolamine Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical group 0.000 description 2
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 2
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 2
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 2
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 229940029575 guanosine Drugs 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 2
- 235000019477 peppermint oil Nutrition 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 230000005068 transpiration Effects 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- ZENOXNGFMSCLLL-UHFFFAOYSA-N vanillyl alcohol Chemical group COC1=CC(CO)=CC=C1O ZENOXNGFMSCLLL-UHFFFAOYSA-N 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- AUHDWARTFSKSAC-HEIFUQTGSA-N (2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-(6-oxo-1H-purin-9-yl)oxolane-2-carboxylic acid Chemical compound [C@]1([C@H](O)[C@H](O)[C@@H](CO)O1)(N1C=NC=2C(O)=NC=NC12)C(=O)O AUHDWARTFSKSAC-HEIFUQTGSA-N 0.000 description 1
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical compound CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 1
- RQFCJASXJCIDSX-UHFFFAOYSA-N 14C-Guanosin-5'-monophosphat Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(O)=O)C(O)C1O RQFCJASXJCIDSX-UHFFFAOYSA-N 0.000 description 1
- KZXUORFYMZRABO-UHFFFAOYSA-N 3-aminobutane-1,2,2-triol Chemical compound CC(N)C(O)(O)CO KZXUORFYMZRABO-UHFFFAOYSA-N 0.000 description 1
- 241001237961 Amanita rubescens Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- QGWNDRXFNXRZMB-UUOKFMHZSA-K GDP(3-) Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O QGWNDRXFNXRZMB-UUOKFMHZSA-K 0.000 description 1
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- GRSZFWQUAKGDAV-UHFFFAOYSA-N Inosinic acid Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 240000007707 Mentha arvensis Species 0.000 description 1
- 235000018978 Mentha arvensis Nutrition 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 240000004760 Pimpinella anisum Species 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- 241000218641 Pinaceae Species 0.000 description 1
- 235000005205 Pinus Nutrition 0.000 description 1
- 241000218602 Pinus <genus> Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 241000779819 Syncarpia glomulifera Species 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- SLINHMUFWFWBMU-UHFFFAOYSA-N Triisopropanolamine Chemical compound CC(O)CN(CC(C)O)CC(C)O SLINHMUFWFWBMU-UHFFFAOYSA-N 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- OFBHPPMPBOJXRT-UHFFFAOYSA-N adenylosuccinic acid Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C2=NC=NC(NC(CC(O)=O)C(O)=O)=C2N=C1 OFBHPPMPBOJXRT-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- 239000003788 bath preparation Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- ZDPUTNZENXVHJC-UHFFFAOYSA-N cumingianoside D Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(OP(O)(O)=O)C1O ZDPUTNZENXVHJC-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000010649 ginger oil Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- QGWNDRXFNXRZMB-UHFFFAOYSA-N guanidine diphosphate Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O QGWNDRXFNXRZMB-UHFFFAOYSA-N 0.000 description 1
- ZDPUTNZENXVHJC-UUOKFMHZSA-N guanosine 3'-monophosphate Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@H]1O ZDPUTNZENXVHJC-UUOKFMHZSA-N 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 229940028843 inosinic acid Drugs 0.000 description 1
- 235000013902 inosinic acid Nutrition 0.000 description 1
- 239000004245 inosinic acid Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 235000020130 leben Nutrition 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000036564 melanin content Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- FRQONEWDWWHIPM-UHFFFAOYSA-N n,n-dicyclohexylcyclohexanamine Chemical class C1CCCCC1N(C1CCCCC1)C1CCCCC1 FRQONEWDWWHIPM-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000001909 pimpinella anisum Substances 0.000 description 1
- 239000001739 pinus spp. Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- XKMLYUALXHKNFT-UHFFFAOYSA-N rGTP Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O XKMLYUALXHKNFT-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 230000008417 skin turnover Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940036248 turpentine Drugs 0.000 description 1
- WRPWWVNUCXQDQV-UHFFFAOYSA-N vanillylamine Chemical compound COC1=CC(CN)=CC=C1O WRPWWVNUCXQDQV-UHFFFAOYSA-N 0.000 description 1
- 229940053939 vanillylamine Drugs 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
【解決手段】(A)ダイウイキョウ油、ニオイヒバ油、アトラスシーダ油、ラバンデュラハイブリダ油、ライム油、ハッカ油、セイヨウアカマツ油、ローズマリー油、テレビン油、ジンジャー油、シナモン油またはオイゲノールなどから選ばれる精油;(B)アデノシンのリン酸エステル又はその塩などの、プリン塩基及びその塩からなる群より選択される少なくとも1種を含む外用組成物。
【選択図】なし
Description
項1.以下の(A)成分及び(B)成分を含有する外用組成物:
(A)精油;
(B)プリン塩基及びその塩からなる群より選択される少なくとも1種。
項2.(A)成分が、ダイウイキョウ油、ニオイヒバ油、アトラスシーダ油、ラバンデュラハイブリダ油、ライム油、ハッカ油、セイヨウアカマツ油、ローズマリー油及びテレビン油からなる群より選択される少なくとも1種の精油である、項1に記載の外用組成物。
項3.(A)成分が、ダイウイキョウ油、セイヨウアカマツ油及びラバンデュラハイブリダ油からなる群より選択される少なくとも1種の精油である、項1又は2に記載の外用組成物。
項4.(A)成分が、ダイウイキョウ油、セイヨウアカマツ油及びラバンデュラハイブリダ油の混合物を含む精油である、項1〜3のいずれかに記載の外用組成物。
項5.(A)成分が、ダイウイキョウ油、ニオイヒバ油、アトラスシーダ油、ラバンデュラハイブリダ油、ライム油、ハッカ油、セイヨウアカマツ油、ローズマリー油及びテレビン油の混合物を含む精油である項1〜4のいずれかに記載の外用組成物。
項6.(B)成分が、アデノシンのリン酸エステル又はその塩である、項1〜5のいずれかに記載の外用組成物。
項7.(B)成分が、アデノシン5'−一リン酸又はその塩である、項1〜6のいずれかに記載の外用組成物。
項8.(A)成分の配合割合が、0.00001〜40重量%である、項1〜7のいずれかに記載の外用組成物。
項9.(B)成分の配合割合が、0.01〜20重量%である、項1〜8のいずれかに記載の外用組成物。
項10.(B)成分1重量部に対する(A)成分の配合比率が、0.0000005〜1000重量部である、項1〜9のいずれかに記載の外用組成物。
項11.皮膚におけるIGF-1分泌促進用である、項1〜10のいずれかに記載の外用組成物。
項12.皮膚における角層水分量増加用である、項1〜10のいずれかに記載の外用組成物。
項13.皮膚における経表皮水分喪失量(TEWL)調節用である、項1〜10のいずれかに記載の外用組成物。
項14.化粧料または医薬部外品の形態である、項1〜13のいずれかに記載の外用組成物。
項15.下記(A)成分及び(B)成分
(A)精油;
(B)プリン塩基及びその塩からなる群より選択される少なくとも1種
を配合することを特徴とする、IGF-1分泌促進用外用組成物の製造方法。
項16.皮膚におけるIGF-1分泌促進用組成物の製造ための下記(A)成分及び(B)成分の使用:
(A)精油;
(B)プリン塩基及びその塩からなる群より選択される少なくとも1種。
項17.下記(A)成分及び(B)成分
(A)精油;
(B)プリン塩基及びその塩からなる群より選択される少なくとも1種
を皮膚に塗布することを特徴とする、皮膚におけるIGF-1分泌促進方法。
項18.下記(A)成分及び(B)成分
(A)精油;
(B)プリン塩基及びその塩からなる群より選択される少なくとも1種
を皮膚に塗布することを特徴とする、老人性乾皮症の予防/治療方法。
項19.カプサイシン類と、プリン塩基及びその塩からなる群より選択される少なくとも1種とを含有する外用組成物。
項20.カプサイシン類が、カプサイシン((6E)-N-[(4-Hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide)、ノニル酸ワニリルアミド(N-Vanillylnonanamide)及びジヒドロカプシエイトからなる群より選択される少なくとも1種である、項19に記載の外用組成物。
本発明の皮膚外用組成物は、下記精油(以下(A)成分と表記することがある)及びプリン塩基及び/又はその塩(以下(B)成分と表記することがある)を含有する。以下、本発明の構成について詳述する。
本発明において(A)成分として使用される精油(エッセンシャル・オイル)とは、植物の花、葉、果実、根、樹皮等から得られる揮発性、親油性の芳香物質を含有する抽出液を指し、好ましくは植物の葉、果実、根、樹皮等から得られる揮発性、親油性の芳香物質を含有する抽出液を指す。
本発明において使用される(B)成分としては、プリン塩基及びその塩からなる群より選択される少なくとも1種が挙げられる。本発明においてプリン塩基とは、プリン又はプリン核を骨格とする各種の誘導体(以下、プリン塩基という)を指す。
本発明の外用組成物は、通常弱酸性〜中性の範囲内のpHを備えていればよいが、皮膚に対する低刺激性、及び色素沈着改善効果の点からは、好ましくはpH5〜7、更に好ましくはpH5.5〜7である。本発明の外用組成物のpHを上記範囲に調整するために、該皮膚外用剤にpH調整剤を配合することができる。このように配合されるpH調整剤としては、弱アルカリ性〜アルカリ性であって薬学的或いは香粧的に許容されるものであれば特に制限されない。一例として、水酸化ナトリウム、L−アルギニン、アミノメチルプロパンジオール、ジイソプロパノールアミン、トリエタノールアミン等を挙げることができる。
さらに本発明者らは、下記実施例において示されるように、カプサイシン類とプリン塩基及び/又はその塩((B)成分)とを併用することによってIGF−1の分泌が促進されることを見出した。従って、本発明は、上記(B)成分とカプサイシン類を含有する外用組成物をも提供する。ただし、ここで記すカプサイシン類とは、精油の特徴である香りや揮発性を有しないことから、精油には含まれず、区別されるものである。
皮膚におけるIGF−1分泌量に及ぼす精油の作用がAMPによりどのように影響されるかを検討するため、精油とAMPを含有する下記組成物(実施例1〜3及び比較例1〜5)を常法により調製した。各組成物のpHは、pH6.5〜7.0になるようにNaOHで調整した。
[試験1−1]
ヘアレスマウス(Hos:HR-1,日本エスエルシー(株), 雌, 6〜8週令)の背部皮膚(3 cm × 5 cm)に被験液を400μL塗布した。塗布30分後に皮膚を採取、凍結破砕した後、皮膚中IGF−1濃度を測定した。IGF−1濃度の測定にはQuantikine(登録商標) Mouse IGF-1 Immunoassay(R&D Systems, Inc.)を使用した。
試験1−1に記載の方法に従って、分泌されたIGF−1濃度を測定した。試験群は下記表3の通りとし、被験液には上記表1に示す組成物を用いた。結果を図1bに示す(平均値±標準誤差)。
試験1−1に記載の方法に従って、分泌されたIGF−1濃度を測定した。試験群は下記表4の通りとし、被験液には表1に示す組成物を用いた。結果を図1cに示す(平均値±標準誤差)。
上記表1に示される実施例1において精油の代わりに、ノニル酸ワニリルアミド((東京化成工業株式会社製);濃度0.001%)を用い、試験例1と同様に被験液を調製し、これを参考例1とした。また、参考例1においてノニル酸ワリニルアミドを含有しない被験液(比較例6)、参考例1においてAMPを含有しない被験液(比較例7)をそれぞれ対照として用いた。
ヘアレスマウス(Hos:HR-1,日本エスエルシー(株), 雌, 7週令)の背部皮膚(3 cm × 5 cm)に被験液を300μL塗布した。塗布30分後に皮膚を採取、凍結破砕した後、皮膚中IGF−1濃度を測定した。IGF−1濃度の測定にはQuantikine(登録商標) Mouse IGF-1 Immunoassay(R&D Systems, Inc.)を使用した。
本試験例は、健常男性9名、年齢30〜55歳(平均45歳)を被験者として行われた。被験者の左右の大腿部正面に設置した5×8cmの領域を試験部位とした。左右一方の試験部位に試験液を塗布し、他方の試験部位は無塗布とした。塗布量は、1回につき約0.1g(使用した容器の2滴分)を、1日2回(午前・午後)とし、塗布時間帯は午前塗布を6:00から12:00までの間、午後塗布を18:00から24:00までの入浴後とした。試験液として、下記表7に示される組成のスキンミルクを用いた。
SKICON-200(アイ・ビイ・エス株式会社)を用いて電気伝導度(μS)を測定し角層水分量の指標とした。測定は7回実施し、中央の5データの平均値を測定値とした。
DermaLab(Cortex Technology)を用いて経表皮水分喪失量(g/ h・m2)を測定する。測定は5回実施し、その平均値を測定値とした。
有意差検定として、無塗布群に対する塗布群の差について、各測定日(塗布4週後、塗布8週後)での比較として対応のあるt検定を用いた。図中、#はP<0.05で有意差があったことを示す。
柔軟性及び弾力性はCutometer MPA580(CK electronic GmbH)を用いて測定する。測定は、機器に付属の説明書に記載される標準的な方法で実施した。測定は5回実施し、その平均値を測定値とした。
有意差検定として、無塗布群に対する塗布群の差について、各測定日(塗布4週後、塗布8週後)での比較として対応のあるt検定を用いた。図中、#はP<0.05で有意差があったことを示す。
皮膚表面きめの評価は、皮膚検体サンプルを作製して行った。皮膚検体サンプルは、反射用レプリカ解析システムASA-03R(アサヒバイオメッド)を用い、付属の説明書に記載される方法で皮膚表面形態のレプリカを作成し、画像撮影して評価した。
これらの効果が全身で示されることを確認する目的で、下記試験を実施した。本試験例は、健常男性7名、年齢39〜57歳(平均49.0歳)を被験者として行われた。被験者の左右一方の踵部に4×4 cmの領域を設置し、これを試験部位とした。左右一方の試験部位に試験液(AMP0.5%と精油混合物0.03%を含むクリーム製剤)を塗布し、他方の試験部位は無塗布とした。塗布量は、1回につき約0.2gを、1日2回(午前・午後)とし、塗布時間帯は午前塗布を6:00から12:00までの間、午後塗布を18:00から24:00までの入浴後とした。
本試験例は、健常男性5名、年齢47〜57歳(平均53.2歳)を被験者として行われた。被験者の左右の前腕内側部に4×4 cmの領域をそれぞれ2カ所ずつ(肘側と手首側)設置し、これを試験部位とした。左右一方の肘側塗布部位に試験液(上記試験例3で用いたスキンミルク)を塗布、他方の肘側塗布部にアデノシン一リン酸及び精油を含有しない市販の一般的なスキンミルク(一般製剤)を塗布した。塗布回数は1日2回(午前・午後)とし、塗布時間帯は午前塗布を6:00から12:00までの間、午後塗布を18:00から24:00までの入浴後とした。塗布量は1回につき約0.05g(使用した容器の1滴分)とした。
以下に本発明の外用組成物の処方例を示すが、本発明はこれらに限定されない。ローション、乳液及び美容液は、各処方例に示される組成に基づいて常法により調製することができる。なお、各処方例の合計量を100重量%として記載する。
Claims (2)
- 以下の(A)成分及び(B)成分を含有する外用組成物:
(A)精油;
(B)プリン塩基及びその塩からなる群より選択される少なくとも1種。 - (B)成分が、アデノシンのリン酸エステル又はその塩である、請求項1に記載の外用組成物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009229984A JP5946234B2 (ja) | 2008-06-09 | 2009-10-01 | 外用組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008150847 | 2008-06-09 | ||
| JP2008150847 | 2008-06-09 | ||
| JP2008222246 | 2008-08-29 | ||
| JP2008222246 | 2008-08-29 | ||
| JP2009229984A JP5946234B2 (ja) | 2008-06-09 | 2009-10-01 | 外用組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009531683A Division JP4403467B1 (ja) | 2008-06-09 | 2009-04-22 | 外用組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010077130A true JP2010077130A (ja) | 2010-04-08 |
| JP2010077130A5 JP2010077130A5 (ja) | 2012-06-07 |
| JP5946234B2 JP5946234B2 (ja) | 2016-07-05 |
Family
ID=41416613
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009531683A Active JP4403467B1 (ja) | 2008-06-09 | 2009-04-22 | 外用組成物 |
| JP2009229984A Active JP5946234B2 (ja) | 2008-06-09 | 2009-10-01 | 外用組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009531683A Active JP4403467B1 (ja) | 2008-06-09 | 2009-04-22 | 外用組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10966983B2 (ja) |
| EP (2) | EP2298275B1 (ja) |
| JP (2) | JP4403467B1 (ja) |
| KR (3) | KR101850405B1 (ja) |
| CN (2) | CN102885708B (ja) |
| CA (1) | CA2727272A1 (ja) |
| ES (2) | ES2959848T3 (ja) |
| TW (2) | TWI424855B (ja) |
| WO (1) | WO2009150902A1 (ja) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017020833A (ja) * | 2015-07-08 | 2017-01-26 | 国立大学法人 熊本大学 | 皮膚状態の評価方法 |
| JPWO2017022091A1 (ja) * | 2015-08-04 | 2018-05-24 | 株式会社 資生堂 | 脂肪幹細胞誘引剤を含む、真皮空洞化による皮膚のたるみ又は老化改善剤 |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2960426B1 (fr) * | 2010-05-27 | 2013-02-15 | Oreal | Utilisation de la guanosine pour maintenir et/ou restaurer les proprietes biomecaniques de la peau |
| JP2012188399A (ja) * | 2011-03-11 | 2012-10-04 | Kao Corp | 皮膚保湿剤 |
| FR2974511B1 (fr) * | 2011-04-28 | 2013-08-02 | Rocher Yves Biolog Vegetale | Composition cosmetique comprenant une huile essentielle de lavande et leur utilisation |
| KR102212633B1 (ko) * | 2013-11-29 | 2021-02-08 | (주)아모레퍼시픽 | 에센셜 오일을 함유하는 스트레스성 탈모방지용 화장료 조성물 |
| US20200188291A1 (en) * | 2017-05-17 | 2020-06-18 | Natura Cosméticos S.A. | Liposoluble anti-pollution cosmetic composition, cosmetic product, use and method for preventing and/or treating signs of extrinsic aging |
| BR112019023937B1 (pt) * | 2017-05-17 | 2022-06-21 | Natura Cosméticos S.A. | Composição cosmética de textura óleo, uso e método para prevenção e/ou tratamento dos sinais de envelhecimento extrínseco e estresse cutâneo |
| CN108014034B (zh) * | 2018-01-11 | 2020-11-20 | 广东博然堂生物科技有限公司 | 一种以天然植物提取物为活性成分的防晒护肤品及其制备方法 |
| KR102097302B1 (ko) * | 2018-04-30 | 2020-04-06 | 주식회사 하이솔 | 식물 유래 오일을 유효성분으로 함유하는 모발 성장촉진 또는 탈모방지용 조성물 |
| GB2577748A (en) | 2018-10-05 | 2020-04-08 | This Works Products Ltd | Fragrance compositions |
| CN115778867B (zh) * | 2022-12-29 | 2024-07-09 | 北京理工大学重庆创新中心 | 一种复配保湿剂、带有该复配保湿剂的超分子脂质体保湿乳液及其制备方法 |
| KR20250156367A (ko) | 2024-04-25 | 2025-11-03 | 동의대학교 산학협력단 | 울분꽃나무 추출물을 유효성분으로 포함하는 호흡기 질환 예방 또는 개선용 조성물 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002510608A (ja) * | 1998-04-06 | 2002-04-09 | コグニス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | サンスクリーン |
| JP2002510610A (ja) * | 1998-04-06 | 2002-04-09 | コグニス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | リボ核酸またはデオキシリボ核酸を含有する化粧または医薬製剤 |
| JP2003081840A (ja) * | 2001-07-04 | 2003-03-19 | Rohto Pharmaceut Co Ltd | 清涼化方法、清涼化剤および外用組成物 |
| KR20030024322A (ko) * | 2001-09-18 | 2003-03-26 | 한국화장품주식회사 | 피부 탄력 개선제로서 사이클릭아데노신-3',5'-일인산을포함하는 화장료 조성물 |
| CN1429540A (zh) * | 2001-12-31 | 2003-07-16 | 高希尔 | 含动物核酸irna活性成分的化妆品及其制造方法 |
| JP2006151971A (ja) * | 2004-11-05 | 2006-06-15 | Maruishi Pharmaceutical Co Ltd | インスリン様成長因子−1分泌促進剤 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03255031A (ja) | 1990-03-02 | 1991-11-13 | Taiyo Koryo Kk | 歯周病予防組成物 |
| WO2000024365A1 (en) * | 1998-10-26 | 2000-05-04 | University Of Massachusetts | Treatment of skin with adenosine or adenosine analog |
| JP2001288046A (ja) * | 2000-03-31 | 2001-10-16 | Shiseido Co Ltd | 頭皮頭髪用組成物 |
| DE20022691U1 (de) * | 2000-07-29 | 2002-02-28 | Dibropharm GmbH Distribution & Co. KG, 76532 Baden-Baden | Hautpflegemittel |
| AU2407902A (en) | 2000-11-22 | 2002-06-03 | Otsuka Pharma Co Ltd | O/w emulsion composition and method of preparing the same |
| JP3994257B2 (ja) | 2000-11-22 | 2007-10-17 | 大塚製薬株式会社 | O/w型乳化組成物及びその調製方法 |
| US7820636B2 (en) | 2001-04-13 | 2010-10-26 | Otsuka Pharmaceutical Co., Ltd. | Sugar intake promoters |
| CN100471502C (zh) | 2002-04-09 | 2009-03-25 | 大塚制药株式会社 | 细胞增殖用组合物 |
| JP4129574B2 (ja) * | 2002-08-06 | 2008-08-06 | 大塚製薬株式会社 | 老化防止剤 |
| JP2004238386A (ja) * | 2002-12-11 | 2004-08-26 | Mikimoto Pharmaceut Co Ltd | 医薬品、医薬部外品および化粧品 |
| CN1244349C (zh) * | 2003-01-15 | 2006-03-08 | 邬纯忠 | 一种治秃生发外用制剂的制备方法 |
| US20040161435A1 (en) | 2003-02-14 | 2004-08-19 | Gupta Shyam K. | Skin Firming Anti-Aging Cosmetic Mask Compositions |
| EP2368602A1 (en) * | 2003-03-03 | 2011-09-28 | Takasago International Corporation | Deodorant perfume composition comprising essential oils for masking an acid odour |
| WO2004089357A2 (en) * | 2003-04-02 | 2004-10-21 | Regents Of The University Of Minnesota | Anti-fungal formulation of triterpene and essential oil |
| JP2004323401A (ja) | 2003-04-23 | 2004-11-18 | Mikimoto Pharmaceut Co Ltd | 皮膚外用剤 |
| CA2541584C (en) | 2003-10-08 | 2013-02-26 | Otsuka Pharmaceutical Co., Ltd. | Composition for promoting collagen production comprising a purine nucleic acid-related substance and a pyrimidine nucleic acid-related substance |
| ATE437625T1 (de) * | 2004-03-25 | 2009-08-15 | Showa Denko Kk | Hautpflege- und kosmetisches präpart mit einem inositol-derivat |
| KR20060040550A (ko) | 2004-11-05 | 2006-05-10 | 마루이시세이야쿠가부시키가이샤 | 인슐린유사 성장인자-1 분비촉진제 |
| JP4925579B2 (ja) | 2004-12-28 | 2012-04-25 | 大塚製薬株式会社 | 水中油型エマルジョンからなる固形組成物 |
| US9399030B2 (en) * | 2005-02-01 | 2016-07-26 | Ajinomoto Co., Inc. | Topically applied circulation enhancing agent and skin and hair cosmetic and bath agent containing the same |
| JP2006225271A (ja) | 2005-02-15 | 2006-08-31 | Otsuka Pharmaceut Co Ltd | シワの予防又は改善剤 |
| US7776915B2 (en) | 2005-03-24 | 2010-08-17 | Tracie Martyn International, Llc | Topical formulations and methods of use |
| KR20080078795A (ko) * | 2005-12-26 | 2008-08-28 | 라이온 가부시키가이샤 | 두피 모발 화장료 |
| DE102006050984A1 (de) * | 2006-10-26 | 2008-04-30 | Henkel Kgaa | Leistungsgesteigerte kosmetische Mittel mit Purin und/oder Purinderivaten |
-
2009
- 2009-04-22 ES ES18150042T patent/ES2959848T3/es active Active
- 2009-04-22 KR KR1020177003652A patent/KR101850405B1/ko active Active
- 2009-04-22 KR KR1020097026200A patent/KR101746743B1/ko active Active
- 2009-04-22 CN CN201210383098.4A patent/CN102885708B/zh active Active
- 2009-04-22 JP JP2009531683A patent/JP4403467B1/ja active Active
- 2009-04-22 EP EP09762333.4A patent/EP2298275B1/en active Active
- 2009-04-22 CA CA2727272A patent/CA2727272A1/en not_active Abandoned
- 2009-04-22 KR KR1020097022487A patent/KR101023503B1/ko active Active
- 2009-04-22 ES ES09762333.4T patent/ES2671040T3/es active Active
- 2009-04-22 US US12/996,929 patent/US10966983B2/en active Active
- 2009-04-22 EP EP18150042.2A patent/EP3335693B1/en active Active
- 2009-04-22 CN CN2009801009462A patent/CN101854911B/zh active Active
- 2009-04-22 WO PCT/JP2009/058022 patent/WO2009150902A1/ja not_active Ceased
- 2009-04-23 TW TW098113461A patent/TWI424855B/zh active
- 2009-04-23 TW TW102148294A patent/TWI507212B/zh active
- 2009-10-01 JP JP2009229984A patent/JP5946234B2/ja active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002510608A (ja) * | 1998-04-06 | 2002-04-09 | コグニス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | サンスクリーン |
| JP2002510610A (ja) * | 1998-04-06 | 2002-04-09 | コグニス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | リボ核酸またはデオキシリボ核酸を含有する化粧または医薬製剤 |
| JP2003081840A (ja) * | 2001-07-04 | 2003-03-19 | Rohto Pharmaceut Co Ltd | 清涼化方法、清涼化剤および外用組成物 |
| KR20030024322A (ko) * | 2001-09-18 | 2003-03-26 | 한국화장품주식회사 | 피부 탄력 개선제로서 사이클릭아데노신-3',5'-일인산을포함하는 화장료 조성물 |
| CN1429540A (zh) * | 2001-12-31 | 2003-07-16 | 高希尔 | 含动物核酸irna活性成分的化妆品及其制造方法 |
| JP2006151971A (ja) * | 2004-11-05 | 2006-06-15 | Maruishi Pharmaceutical Co Ltd | インスリン様成長因子−1分泌促進剤 |
Non-Patent Citations (2)
| Title |
|---|
| JPN6013059573; J Biol Chem., Vol.272 No.38 p.23498-23502 (1997) * |
| JPN6013059575; Growth Hormone & IGF Res., Vol.17 No.2, p.171-176 (2007) * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017020833A (ja) * | 2015-07-08 | 2017-01-26 | 国立大学法人 熊本大学 | 皮膚状態の評価方法 |
| JPWO2017022091A1 (ja) * | 2015-08-04 | 2018-05-24 | 株式会社 資生堂 | 脂肪幹細胞誘引剤を含む、真皮空洞化による皮膚のたるみ又は老化改善剤 |
| US10918590B2 (en) | 2015-08-04 | 2021-02-16 | Shiseido Company, Ltd. | Fat stem cell attractant-containing agent for improving skin looseness or aging caused by dermal cavitation |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2298275A1 (en) | 2011-03-23 |
| KR101023503B1 (ko) | 2011-03-21 |
| WO2009150902A1 (ja) | 2009-12-17 |
| CN101854911A (zh) | 2010-10-06 |
| KR20170019477A (ko) | 2017-02-21 |
| KR101850405B1 (ko) | 2018-04-19 |
| US10966983B2 (en) | 2021-04-06 |
| EP3335693B1 (en) | 2023-09-13 |
| US20110081429A1 (en) | 2011-04-07 |
| TW200950815A (en) | 2009-12-16 |
| TW201417837A (zh) | 2014-05-16 |
| CN102885708A (zh) | 2013-01-23 |
| CN101854911B (zh) | 2012-11-28 |
| KR101746743B1 (ko) | 2017-06-13 |
| CN102885708B (zh) | 2015-03-18 |
| TWI424855B (zh) | 2014-02-01 |
| ES2671040T3 (es) | 2018-06-04 |
| CA2727272A1 (en) | 2009-12-17 |
| JP4403467B1 (ja) | 2010-01-27 |
| TWI507212B (zh) | 2015-11-11 |
| ES2959848T3 (es) | 2024-02-28 |
| EP2298275A4 (en) | 2013-12-18 |
| JPWO2009150902A1 (ja) | 2011-11-10 |
| KR20100029741A (ko) | 2010-03-17 |
| KR20110005628A (ko) | 2011-01-18 |
| EP2298275B1 (en) | 2018-04-11 |
| HK1179514A1 (en) | 2013-10-04 |
| EP3335693A1 (en) | 2018-06-20 |
| JP5946234B2 (ja) | 2016-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4403467B1 (ja) | 外用組成物 | |
| JP6968534B2 (ja) | ピキア・アノマーラ及びチコリ根抽出物を含む局所用組成物 | |
| WO2002053127A1 (en) | Agents for inhibiting or restoring skin damage caused by drying and method of evaluating the same | |
| KR20080031156A (ko) | 헤어 토닉 | |
| JP2019108278A (ja) | しわ改善剤 | |
| WO2006000708A1 (fr) | Composition comprenant un extrait de lotus bleu a effet decontractant de la peau. | |
| HK1179514B (en) | Composition for external use | |
| KR102281403B1 (ko) | 비자 세라마이드와 울금 및 동백유박 추출물을 포함하는 피부 주름 개선용 화장료 조성물 | |
| JP2007161662A (ja) | アドバンスド・グリケーション・エンドプロダクツ分解用の化粧料 | |
| JPH06271446A (ja) | しわ改善剤 | |
| RU2299726C2 (ru) | Лечебно-профилактическая противоинфекционная губная помада | |
| HK1154778A (en) | Composition for external use | |
| HK1154778B (en) | Composition for external use | |
| EP3970691A1 (fr) | Compositions cosmétiques amincissantes contenant un ou plusieurs limonoïdes | |
| JP2002037715A (ja) | 育毛剤 | |
| JP2002275044A (ja) | 皮膚化粧料 | |
| JP2004035516A (ja) | 脂肪分解促進剤および痩身用皮膚化粧料 | |
| JP2001172133A (ja) | 育毛剤 | |
| KR20180108252A (ko) | 미리시트린을 포함하는 화장료 조성물 | |
| JP2001213751A (ja) | 化粧料組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120419 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120419 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130813 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130918 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130920 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131203 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131218 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140805 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141029 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20141105 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20141226 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160212 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160311 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160531 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5946234 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |